This collaboration will enable the implementation of a thorough evaluation of APTA-1’s biological effects. It will, among other things, help to clarify the anti-inflammatory properties of APTA-1. It is these anti-inflammatory properties that are central to the successful treatment of diseases like stroke.
Red Glead is working on the formulation and stability for Aptahem’s lead candidate drug, Apta-1.
TKT works with Aptahem’s toxicological programme for safety for Apta-1.
We help our customers translate preclinical projects into clinical success and offer services in three main areas: 1) strategic planning, 2) preclinical pharmacology and 3) personalized medicine
Truly Labs AB is a pre-clinical CRO that provides customized in vitro and in vivo services.
Aptahem and Truly collaborate on the preclinical drug development and safety programme for Apta-1.
JCDC is responsible for planning Aptahem’s clinical phase I/IIa studies.